Abstract: The present invention relates to a multi-layer lithium metal battery negative electrode, and a preparation method and preparation device therefor. The multi-layer lithium metal battery negative electrode comprises a current collector, a lithium metal layer, a fast ion conductor layer and a functional protection layer. The present invention also relates to a method for preparing the multi-layer lithium metal battery negative electrode, the method characterized by comprising the following steps: (1) a step of evaporating a lithium metal; (2) a step of evaporating a fast ion conductor; and (3) a step of coating a protective material and a polymer solid electrolyte. In addition, the present invention relates to a device for preparing the multi-layer lithium metal battery negative electrode.

Abstract: The present disclosure provides a cleaning assembly including a cleaning performing device. The cleaning performing device includes a cleaning module configured to clean a surface and a cleaning driving module configured to drive the cleaning module to move relative to the surface, a driving device configured to drive the cleaning performing device to be lifted or lowered, and a constraining structure configured to constrain a lifting or lowering trajectory of the cleaning performing device. The present disclosure further provides a cleaning apparatus. The cleaning performing device can be lifted or lowered according to an actual need, such that improves an adaptability of the cleaning apparatus. Further, the lifting or lowering trajectory of the cleaning performing device can be constrained by the constraining structure, such that improves a stability of the cleaning apparatus during moving up and down.

Abstract: A circuit is disclosed. The circuit includes a transformer having a primary winding extending between a first terminal and a second terminal, and further including a secondary winding extending between a third terminal and a first output terminal; a first switch having a first gate terminal, a first source terminal and a first drain terminal, the first drain terminal coupled to the second terminal and the first source terminal coupled to a power source; a second switch having a second gate terminal, a second source terminal and a second drain terminal, the second source terminal coupled to the second terminal, and the second drain terminal coupled to the power source; and a third switch having a third gate terminal, a third source terminal and a third drain terminal, the third source terminal coupled to the third terminal and the third drain terminal coupled to a second output terminal.

Abstract: Disclosed is a cleaning robot. The cleaning robot includes a body, a traveling assembly, a rolling brush assembly, a dust suction assembly, a mopping assembly, and a universal wheel. The traveling assembly, the rolling brush assembly, the dust suction assembly, the mopping assembly, and the universal wheel are all arranged on the body. The dust suction assembly includes a dust box. The rolling brush assembly is configured for sweeping garbage on a ground. The dust box is configured for receiving garbage swept by the rolling brush assembly. In an advancing direction of the cleaning robot, the dust box is arranged in front of the rolling brush assembly, and the mopping assembly and/or the universal wheel is arranged behind the rolling brush assembly.

Abstract: Improved methods for treating neoplastic diseases such as cancer are provided by using muteins of human tumor necrosis factor-alpha (TNF-?). Compared to wild-type human TNF-? these therapeutic TNF muteins have higher specific anti-tumor activity, but with much reduced systemic toxicity and milder side effects such chills and fever. In addition, potentially synergistic, novel combinations of the inventive TNF-? muteins with other anti-neoplastic agents are provided for effectively treating patients having particular types of cancer or malignancy or at particular stages of cancer development, and for mitigating resistance of the patients to treatment of non-TNF antineoplastic agents.

Abstract: Improved methods for treating neoplastic diseases such as cancer are provided by using muteins of human tumor necrosis factor-alpha (TNF-&agr;). Compared to wild-type human TNF-&agr; these therapeutic TNF muteins have higher specific anti-tumor activity, but with much reduced systemic toxicity and milder side effects such chills and fever. In addition, potentially synergistic, novel combinations of the inventive TNF-&agr; muteins with other anti-neoplastic agents are provided for effectively treating patients having particular types of cancer or malignancy or at particular stages of cancer development.